These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 24770796)

  • 1. Infliximab has no apparent effect in the inner ear hearing function of patients with rheumatoid arthritis and ankylosing spondylitis.
    Toktas H; Okur E; Dundar U; Dikici A; Kahveci OK
    Clin Rheumatol; 2014; 33(10):1481-7. PubMed ID: 24770796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
    J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
    Gonnet-Gracia C; Barnetche T; Richez C; Blanco P; Dehais J; Schaeverbeke T
    Clin Exp Rheumatol; 2008; 26(3):401-7. PubMed ID: 18578960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lower concentration of vitamin D is associated with lower DAS28 and VAS-pain scores in patients with inflammatory rheumatic diseases treated with infliximab: a pilot study.
    Miler M; Nikolac Gabaj N; Grazio S; Vahtarić A; Vrtarić A; Grubišić F; Skala Kavanagh H; Doko Vajdić I; Vrkić N
    Rheumatol Int; 2020 Sep; 40(9):1455-1461. PubMed ID: 32462255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab improves bone metabolism and bone mineral density in rheumatoid arthritis and ankylosing spondylitis: a prospective 2-year study.
    Dischereit G; Tarner IH; Müller-Ladner U; Lange U
    Clin Rheumatol; 2013 Mar; 32(3):377-81. PubMed ID: 23179009
    [No Abstract]   [Full Text] [Related]  

  • 7. TNFα antagonist therapy does not increase the Epstein-Barr virus burden in patients with rheumatoid arthritis or ankylosing spondylitis.
    Couderc M; Payet S; Henquell C; Dubost JJ; Soubrier M
    Joint Bone Spine; 2010 Oct; 77(5):414-7. PubMed ID: 20542718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.
    Elkayam O; Bashkin A; Mandelboim M; Litinsky I; Comaheshter D; Levartovsky D; Mendelson E; Wigler I; Caspi D; Paran D
    Semin Arthritis Rheum; 2010 Jun; 39(6):442-7. PubMed ID: 19246078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Augmentation index in patients with rheumatoid arthritis and ankylosing spondylitis treated with infliximab.
    Pieringer H; Stuby U; Pohanka E; Biesenbach G
    Clin Rheumatol; 2010 Jul; 29(7):723-7. PubMed ID: 20162315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis.
    Kiortsis DN; Mavridis AK; Filippatos TD; Vasakos S; Nikas SN; Drosos AA
    J Rheumatol; 2006 May; 33(5):921-3. PubMed ID: 16541480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of TNF alpha inhibition on plasma fibrinolytic balance in patients with chronic inflammatory rheumatical disorders.
    Agirbasli M; Inanc N; Baykan OA; Direskeneli H
    Clin Exp Rheumatol; 2006; 24(5):580-3. PubMed ID: 17181930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in MiRNA-5196 Expression as a Potential Biomarker of Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis Patients.
    Ciechomska M; Bonek K; Merdas M; Zarecki P; Swierkot J; Gluszko P; Bogunia-Kubik K; Maslinski W
    Arch Immunol Ther Exp (Warsz); 2018 Oct; 66(5):389-397. PubMed ID: 29744553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
    Seitz M; Wirthmüller U; Möller B; Villiger PM
    Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antinuclear Antibodies and Lupus-like Manifestations in Rheumatoid Arthritis and Ankylosing Spondylitis Patients at 4 Months' Follow-up After Treatment with Infliximab and Etanercept.
    Aghdashi MA; Khadir M; Dinparasti-Saleh R
    Curr Rheumatol Rev; 2020; 16(1):61-66. PubMed ID: 31057111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis.
    Kiortsis DN; Mavridis AK; Vasakos S; Nikas SN; Drosos AA
    Ann Rheum Dis; 2005 May; 64(5):765-6. PubMed ID: 15458960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reasons for Discontinuation and Adverse Effects of TNFα Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis.
    García-Lagunar MH; Gutiérrez-Cívicos MR; García-Simón MS; Conesa-Zamora P; Jimenez-Santos E; Cano-Vivar P; García-Márquez A; Muñoz-García I; Viney AC
    Ann Pharmacother; 2017 May; 51(5):388-393. PubMed ID: 27920336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safe re-administration of tumor necrosis factor-alpha (TNFα) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFα therapy.
    Suh YS; Kwok SK; Ju JH; Park KS; Park SH; Yoon CH
    J Korean Med Sci; 2014 Jan; 29(1):38-42. PubMed ID: 24431903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.
    Arends S; Brouwer E; van der Veer E; Groen H; Leijsma MK; Houtman PM; Th A Jansen TL; Kallenberg CG; Spoorenberg A
    Arthritis Res Ther; 2011 Jun; 13(3):R94. PubMed ID: 21689401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug survival rates of tumor necrosis factor inhibitors in patients with rheumatoid arthritis and ankylosing spondylitis.
    Kang JH; Park DJ; Lee JW; Lee KE; Wen L; Kim TJ; Park YW; Lee SS
    J Korean Med Sci; 2014 Sep; 29(9):1205-11. PubMed ID: 25246737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis.
    Gengenbacher M; Sebald HJ; Villiger PM; Hofstetter W; Seitz M
    Ann Rheum Dis; 2008 May; 67(5):620-4. PubMed ID: 17720725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.